Morgan Stanley set a $126.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Thursday, Stock Target Advisor reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities research analysts also recently weighed in on ALNY. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, February 5th. Piper Jaffray Companies reduced their target price on shares of Alnylam Pharmaceuticals to $152.00 and set an overweight rating on the stock in a research note on Tuesday, January 15th. UBS Group initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 23rd. They issued a neutral rating and a $87.00 target price on the stock. Evercore ISI initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, April 11th. They issued an outperform rating and a $120.00 target price on the stock. Finally, Needham & Company LLC reissued a buy rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $128.72.
Alnylam Pharmaceuticals stock traded down $5.25 during mid-day trading on Thursday, reaching $77.29. 4,451,783 shares of the company’s stock traded hands, compared to its average volume of 848,332. The company has a market cap of $8.77 billion, a price-to-earnings ratio of -10.21 and a beta of 2.53. The company has a quick ratio of 6.56, a current ratio of 6.69 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $124.21.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.20) by $0.47. The company had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. Alnylam Pharmaceuticals had a negative net margin of 1,016.58% and a negative return on equity of 50.82%. Alnylam Pharmaceuticals’s revenue was up 52.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.22) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -8.68 earnings per share for the current fiscal year.
In other news, Director Philip A. Sharp sold 15,000 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $88.23, for a total value of $1,323,450.00. Following the transaction, the director now directly owns 250,633 shares in the company, valued at $22,113,349.59. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 3.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the fourth quarter. FMR LLC now owns 15,154,553 shares of the biopharmaceutical company’s stock worth $1,104,919,000 after purchasing an additional 54,637 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Alnylam Pharmaceuticals by 0.9% in the third quarter. Vanguard Group Inc now owns 7,605,253 shares of the biopharmaceutical company’s stock worth $665,612,000 after purchasing an additional 66,740 shares during the last quarter. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 7,605,253 shares of the biopharmaceutical company’s stock worth $665,612,000 after acquiring an additional 66,740 shares in the last quarter. BlackRock Inc. grew its holdings in Alnylam Pharmaceuticals by 1.0% during the 4th quarter. BlackRock Inc. now owns 6,145,805 shares of the biopharmaceutical company’s stock worth $448,089,000 after acquiring an additional 61,777 shares in the last quarter. Finally, Baillie Gifford & Co. grew its holdings in Alnylam Pharmaceuticals by 19.8% during the 1st quarter. Baillie Gifford & Co. now owns 5,684,504 shares of the biopharmaceutical company’s stock worth $531,217,000 after acquiring an additional 937,654 shares in the last quarter. Hedge funds and other institutional investors own 86.91% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.